![]() The late Marie-Louise von Franz (1915 -1998) was a Jungian analyst and colleague/student of Carl Jung. In Man and His Symbols, von Franz described active imagination as follows: "Active imagination is a certain way of meditating imaginatively, by which one may deliberately enter into contact with the unconscious and make a conscious connection with psychic phenomena." She also wrote on subjects such as alchemy, discussed from the Jungian, psychological perspective, and active imagination, which could be described as conscious dreaming. Von Franz also wrote over 20 volumes on Analytical psychology, most notably on fairy tales as they relate to Archetypal or Depth Psychology, most specifically by amplification of the themes and characters. In The Way of the Dream she claims to have interpreted over 65,000 dreams. In addition to her many books, Von Franz recorded a series of films in 1987 titled The Way of the Dream with her student Fraser Boa. She cites the reference to the publication in an expanded essay Symbols of the Unus Mundus, published in her book Psyche and Matter. ![]() Von Franz, in 1968, was the first to publish that the mathematical structure of DNA is analogous to that of the I Ching. Two of her books, Number and Time and Psyche and Matter deal with this research. Due to his age, he turned the problem over to von Franz. He also believed that this concept of the unus mundus could be investigated through research on the archetypes of the natural numbers. Jung believed in the unity of the psychological and material worlds, i.e., they are one and the same, just different manifestations. Von Franz worked with Carl Jung, whom she met in 1933 and knew until his death in 1961. doi: 10.1056/nejm199311113292004.Marie-Louise von Franz was a Swiss Jungian psychologist and scholar. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Lewis EJ, Hunsicker LG, Clarke WR, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ![]() Webster AC, Nagler EV, Morton RL, Masson P. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. ![]() (Funded by Boehringer Ingelheim and others EMPA-KIDNEY number, NCT03594110 EudraCT number, 2017-002971-24.).Ĭopyright © 2022 Massachusetts Medical Society.įox CS, Matsushita K, Woodward M, et al. The rates of serious adverse events were similar in the two groups.Īmong a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86 95% CI, 0.78 to 0.95 P = 0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72 95% confidence interval, 0.64 to 0.82 P<0.001). The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to <10 ml per minute per 1.73 m 2, a sustained decrease in eGFR of ≥40% from baseline, or death from renal causes) or death from cardiovascular causes.Ī total of 6609 patients underwent randomization. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m 2 of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m 2 with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. ![]()
0 Comments
Leave a Reply. |